The Full Risk–Benefit Balance Behind the First Covid-19 Vaccine
The Full Risk–Benefit Balance Behind the First Covid-19 Vaccine by Yaakov Ophir at Brownstone Institute Health Secretary Robert F. Kennedy, Jr.’s recent decision to terminate the Covid-19 Emergency Use Authorization (EUA) declarations1 invites reconsideration of the evidence that launched this extraordinary regulatory chapter. The FDA’s first EUA for a Covid-19 vaccine rested on its determination that the known and potential benefits of the Pfizer–BioNTech vaccine outweighed its known and potential risks. Yet the pivotal trial report did not bring those benefits and risks together within a…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.